Managing Director, MMLC Group
Member of the Law Council
Matthew Murphy is the Managing Director of the MMLC Group in Beijing. Prior to founding the MMLC Group, Mr. Murphy was part of the China and M&A teams at Freshfields Bruckhaus Deringer and led the Asian IP/IT group out of Hong Kong. He specializes in intellectual property, technology, dispute resolution and corporate law. Mr. Murphy is a Panelist in the Hong Kong International Arbitration Centre and in the gTLD Asian Domain Name Dispute Resolution Centre. He is particularly active in international and China patent, trademark and copyright disputes, as well as cross-border restructurings, Asian M&A (including competition law), and general complex international commercial dispute resolution. (This is me - Update Profile)
Opinions and analyses expressed in GLG News are solely those of the author. See the Terms of Use for details.
China's Anti-Monopoly Bureau Approves the Panasonic-Sanyo Transaction
November 11, 2009
China's Anti-Monopoly Bureau Approves the Panasonic-Sanyo Transaction | www.mmlcgroup.com
The Chinese Anti-Monopoly Bureau (AMB) handed down its decision in early November 2009, regarding Panasonic’s acquisition of Sanyo. The AMB approved the transaction subject to divestiture of certain assets. The decision is more comprehensive that previous decisions, although this case was the first to go into a third phase of investigation by the AMB indicating the complications involved.
The Regulation of Online Games in China
October 30, 2009
The Regulation of Online Games in China | www.mmlcgroup.com
The online games industry in China is becoming incredibly profitable, with millions of regular users and an endless thirst for new games and technology. This article looks at the regulations and departments in China that are claiming authority to regulate this space. As expected there is considerable room for improvement, however the regulatory environment is beginning to take shape.
China’s Anti-Monopoly Bureau Approves the Pfizer-Wyeth Transaction
September 29, 2009
China’s Anti-Monopoly Bureau Approves the Pfizer/Wyeth Transaction | www.mmlcgroup.com
On 29 September 2009, China’s Ministry of Commerce (“MOFCOM”) published another decision from its fledgling Anti-Monopoly Bureau (“AMB”), this time concerning the acquisition of Wyeth by US drug heavy-weight, Pfizer. Approval was granted to the transaction, ahead of approval from the US Federal Trade Commission, Australian ACCC and the Canadian Competition authority.
April 27, 2009
China’s New Anti-Monopoly Law – an analysis of recent decisions regarding foreign investment and trade | www.mmlcgroup.com
The new Chinese Anti-Monpoly Bureau ("AMB") has issued a number of controversial decisions in recent months, involving intenational M&A transactions. It has approved most transactions, although many on a conditional basis, but it refused to approve the greatly followed Coca Cola acquisition of Huiyuan. This article looks at the law, the criteria applied by the AMB, the facts and decision issued in a number of cases, and provides guidelines that companies should look at prior to approaching the AMB for approval.
| Study Group Name | No. Members |
|---|---|
| Securities, Corporate Governance, and M&A Experts: Lawyers (Asia) | 304 |
| Lawyers (China) | 240 |
| Intellectual Property Experts: Lawyers (Asia) | 164 |
| Iron Ore Mining Experts | 120 |
| Wind Power Regulation Experts | 51 |
Matthew Murphy has not participated in any GLG Live Meetings.
View all GLG Live Meetings in Legal, Economic & Regulatory Affairs